Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

J Hepatol. 2011 Aug;55(2):322-7. doi: 10.1016/j.jhep.2010.10.037. Epub 2010 Dec 13.

Abstract

Background & aims: Recent studies have described a major impact of genetic variations near the IL28B gene on the natural course and outcome of antiviral therapy in chronic hepatitis C. We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection.

Methods: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide polymorphism were determined in 91 patients with HCV liver graft reinfection, 47 of whom were treated with pegylated interferon-α (PEG-IFN-α) and ribavirin. IL28B genetic polymorphisms were correlated with the natural course and treatment outcome of recurrent hepatitis C.

Results: Patients requiring liver transplantation due to end-stage chronic hepatitis C appeared to be selected toward the adverse genotypes rs12979860 CT/TT compared to non-transplanted HCV-infected patients (p=0.046). Patients with the donor genotype rs12979860 CC had higher peak ALT and HCV RNA serum concentrations than those with CT/TT (p=0.04 and 0.06, respectively). No association was observed between ALT/HCV RNA serum concentrations and recipient genotypes (p>0.3). More important, donor IL28B rs12979860 CC vs. CT/TT genotypes were associated with rapid, complete early, and sustained virologic response (RVR, cEVR, SVR) to treatment with PEG-IFN-α and ribavirin (p=0.003, 0.0012, 0.008, respectively), but weaker associations of recipient genotypes with RVR, cEVR, and SVR were observed as well (p=0.0046, 0.115, 0.118, respectively).

Conclusions: We provide evidence for a dominant, but not exclusive impact of the donor rather than the recipient IL28B genetic background on the natural course and treatment outcome of HCV liver graft reinfection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antiviral Agents / administration & dosage
  • Female
  • Genotype
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / physiopathology
  • Hepatitis C, Chronic / surgery*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferons
  • Interleukins / genetics*
  • Liver Cirrhosis / etiology
  • Liver Transplantation / adverse effects*
  • Liver Transplantation / physiology
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage
  • Polymorphism, Single Nucleotide
  • RNA, Viral / blood
  • Recombinant Proteins / administration & dosage
  • Recurrence
  • Ribavirin / administration & dosage
  • Tissue Donors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • IFNL3 protein, human
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukins
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Interferons
  • Alanine Transaminase
  • peginterferon alfa-2b
  • peginterferon alfa-2a